This is a transformative catalyst for HUTCHMED, the SAFFRON data provide the global registration package for the ORPATHYS + TAGRISSO combination, which could expand the addressable market beyond China. Traders should watch for regulatory submission timelines (FDA, EMA) and potential partnership milestones from AstraZeneca. The stock may gap up significantly on this news given the high unmet need and biomarker-directed nature of the therapy.
Drugs in focus
HCM drug pipeline →ORPATHYS
◆ Mixed Named in this press release- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 18 $12.64entry
- T+1 · 3mo ago −0.40%α −0.61% · $12.59
- T+5 · 3mo ago −3.01%α −2.81% · $12.26
- T+20 · 2mo ago +6.49%α +8.23% · $13.46
- T+60 · 6d ago +21.68%α +23.72% · $15.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) significantly improved progression-free survival and overall survival vs chemotherapy in EGFR-mutant NSCLC patients with MET-driven resistance after TAGRISSO progression. This is a high-impact catalyst for global registration of the combination, addressing a large unmet need in a biomarker-defined population with no prior oral targeted option.
Key Facts
- SAFFRON Phase III met primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness
- Trial enrolled 338 patients across 29 countries in 230 centers
- Combination addresses MET overexpression/amplification, which occurs in ~34% of patients after third-generation EGFR TKI progression
- ORPATHYS plus TAGRISSO already approved in China based on SACHI Phase III; SAFFRON supports global registrations
- Safety profile consistent with known profiles of each medicine; no new safety findings
- Data to be presented at forthcoming medical meeting and shared with global regulatory authorities
Financial Impact
Positive readout for a global Phase III trial in a large addressable NSCLC population with MET-driven resistance; potential to unlock multi-billion-dollar peak sales for the combination globally
Risk Factors
- Regulatory timelines and approval decisions are uncertain; FDA/EMA may require additional data
- Competition from other MET-targeted agents in development
- Commercial uptake depends on biomarker testing adoption (MET IHC/FISH) in clinical practice
- HUTCHMED CEO currently on leave of absence, which may create operational uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345800 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers